RxDoctor Payments Data

Samar El-Sayegh, MD

Psychiatry · Ashtabula, OHNPI 1801016951

Payments from drug & device makers

$977in general payments, 2019–2025

Across 45 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$237
  • E.r. Squibb & Sons, L.L.C.$145
  • Johnson & Johnson$125
  • AbbVie$88
  • Otsuka America Pharmaceutical, Inc.$79
  • Lundbeck LLC$68
  • plus $237 from 7 others

What the payments were for

  • Food & beverage$95097%
  • Education$273%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$977 in reported general payments places this provider in the 70th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$26,537
Medicare patients
106
Services billed
287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole73$107,681
Wellbutrin XlBupropion Hcl18$44,293
LatudaLurasidone Hcl11$14,673
Aripiprazole151$13,394
ZyprexaOlanzapine11$10,215
Duloxetine Hcl317$6,815
Olanzapine OdtOlanzapine27$4,744
Quetiapine Fumarate176$4,650
Buspirone Hcl264$3,753
Ziprasidone Hcl81$3,699
Clozapine19$2,999
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine47$2,876
Bupropion XlBupropion Hcl180$2,607
Escitalopram Oxalate277$2,536
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine84$2,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$79$107,68173 claims
Sunovion Pharmaceuticals Inc.Latuda$24$14,67311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Ashtabula

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →